Abstract:Histone deacetylase (HDAC) inhibitors possess therapeutic potential to reverse aberrant epigenetic changes associated with cancers, neurological diseases, and immune disorders. Unfortunately, clinical studies with some HDAC inhibitors displayed delayed cardiac adverse effects, such as atrial fibrillation and ventricular tachycardia. However, the underlying molecular mechanism(s) of HDAC inhibitor-mediated cardiotoxicity remains poorly understood and is difficult to detect in the early stages of preclinical drug development because of a delayed onset of effects. In the present study, we show for the first time in human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) that HDAC inhibitors (dacinostat, panobinostat, vorinostat, entinostat, and tubastatin-a) induce delayed dose-related cardiac dysfunction at therapeutic concentrations associated with cardiac adverse effects in humans. HDAC inhibitor-mediated delayed effects on the beating properties of hiPS-CMs developed after 12 hours by decreasing the beat rate, shortening the field potential duration, and inducing arrhythmic behavior under form of sustained contractions and fibrillation-like patterns. Transcriptional changes that are common between the cardiotoxic HDAC inhibitors but different from noncardiotoxic treatments identified cardiac-specific genes and pathways related to structural and functional changes in cardiomyocytes. Combining the functional data with epigenetic changes in hiPS-CMs allowed us to identify molecular targets that might explain HDAC inhibitor-mediated cardiac adverse effects in humans. Therefore, hiPS-CMs represent a valuable translational model to assess HDAC inhibitor-mediated cardiotoxicity and support identification of better HDAC inhibitors with an improved benefit-risk profile. Significance: Histone deacetylase (HDAC) inhibitors are a promising class of drugs to treat certain cancers, autoimmune, and neurodegenerative diseases. However, treated patients can experience various cardiac adverse events such as hearth rhythm disorders. This study found that human induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) can predict cardiac adverse events in patients caused by HDAC inhibitors. Furthermore, transcriptional changes at the level of gene expression supported the effects on the beating properties of hiPS-CMs and highlight targets that might cause these cardiac adverse effects. hiPS-CMs represent a valuable translational model to assess HDAC inhibitor-mediated cardiotoxicity and to support development of safer HDAC inhibitors.

HDAC Inhibition: A Novel Therapeutic Target for Pulmonary Hypertension by Reducing Right Ventricular Hypertrophy Through Diverse Pathological Mechanisms

Inhibition of Histone Deacetylases Prevents Cardiac Remodeling After Myocardial Infarction by Restoring Autophagosome Processing in Cardiac Fibroblasts.

Histone Deacetylases in Modulating Cardiac Disease and Their Clinical Translational and Therapeutic Implications

HDAC inhibition as a therapeutic strategy in myocardial ischemia/reperfusion injury

Targeting histone deacetylase in cardiac diseases

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Histone Deacetylase Inhibition Attenuates Cardiomyocyte Hypoxia-Reoxygenation Injury.

Targeting histone deacetylases for heart diseases

Discovery of Herbacetin As a Novel SGK1 Inhibitor to Alleviate Myocardial Hypertrophy

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

HDAC5 inhibition attenuates ventricular remodeling and cardiac dysfunction

Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy

Functional and Transcriptional Characterization of Histone Deacetylase Inhibitor-Mediated Cardiac Adverse Effects in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Histone deacetylase 3 suppresses the expression of SHP-1 via deacetylation of DNMT1 to promote heart failure

HDAC Inhibitors: Therapeutic Potential in Fibrosis-Associated Human Diseases

Effect of the Angiotensin II Receptor Blocker Valsartan on Cardiac Hypertrophy and Myocardial Histone Deacetylase Expression in Rats with Aortic Constriction

Superconducting gravity gradiometer for sensitive gravity measurements. I. Theory.

Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression

Regulation of Acetylation Restores Proteolytic Function of Diseased Myocardium in Mouse and Human

Abstract 10838: HDAC Inhibition Induces Autophagy and Mitochondrial Biogenesis to Maintain Mitochondrial Homeostasis During Cardiac Ischemia/Reperfusion Injury

Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension